Summary by Moomoo AI
CRISPR Therapeutics AG's CEO, Samarth Kulkarni, has completed a transaction involving the company's common stock on 08/08/2024. The action taken was classified as a bona fide gift, with Kulkarni disposing of 100,000 shares at no cost. Following this transaction, Kulkarni directly holds 222,500 shares of CRISPR Therapeutics. Additionally, Kulkarni has an indirect beneficial ownership of 85,622 shares through The Kulkarni 2023 GRAT. The transaction has been reported as completed.